Document
false0001574774 0001574774 2020-02-26 2020-02-26


 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 26, 2020
https://cdn.kscope.io/a3fa444fd1079dd7fdfa9b214e9d41b9-logo1a05.jpg
BioTelemetry, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
000-55039
 
46-2568498
(State or other jurisdiction
 
(Commission
 
(IRS Employer
of incorporation)
 
File Number)
 
Identification No.)
 
1000 Cedar Hollow Road
 
 
Malvern,
Pennsylvania
 
19355
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: (610) 729-7000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.001 per share
BEAT
NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 











Item 2.02 Results of Operations and Financial Condition.
On February 26, 2020, BioTelemetry, Inc. issued a press release announcing its financial results for the fourth quarter ended December 31, 2019. Such information, including the Exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing. A copy of the press release is included herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number
 
Exhibit Title
 
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
 
BioTelemetry, Inc.
 
 
 
 
 
 
 
 
Dated: February 26, 2020
 
By:
/s/ Heather C. Getz
 
 
 
 
 
 
 
Name:
Heather C. Getz
 
 
 
Title:
Executive Vice President and Chief Financial and Administrative Officer



Exhibit
Exhibit 99.1

https://cdn.kscope.io/a3fa444fd1079dd7fdfa9b214e9d41b9-beatlogo.jpg

BioTelemetry, Inc. Reports Fourth Quarter 2019 Financial Results
Announces Record Quarterly and Full Year Results

Malvern, PA – February 26, 2020 – BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the quarter and year ended December 31, 2019.

Quarter Highlights

Recognized quarterly revenue of $112.0 million
Reached 8.1% year-over-year quarterly revenue growth
Achieved 30th consecutive quarter of year-over-year revenue growth
Reported GAAP net income of $1.6 million, or 1.4% of revenue
Realized quarterly adjusted EBITDA of $31.7 million, or 28.3% of revenue
Received coverage from five new Blue Cross companies for MCT services

President and CEO Commentary

Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented:
“Our fourth quarter capped off a strong year for BioTelemetry, highlighted by our highest quarterly revenue and adjusted EBITDA in company history. These results came in at the high end of our expectations and marked the 30th consecutive quarter of year-over-year revenue growth. Healthcare services demand remained robust, with revenue growing 9% on a year-over-year basis, driven primarily by our MCT, extended Holter and Geneva services. We also benefited from continued growth in our Research and digital population health businesses.

“2019 was a solid year for BioTelemetry. We began with the acquisitions of Geneva Health Solutions and ADEA Medical, increasing our addressable market by over $1 billion. The Geneva acquisition provides access to the monitoring of implantable devices and ADEA broadens our reach into Europe. We saw top-line growth across all segments, led by Healthcare services, resulting in record revenue for the year. We invested in information technology, research and development and sales resources, which we expect will enhance our operations and drive growth for years to come. Also during 2019, through our “Heart for Hope” corporate give-back program, we proudly funded life-saving heart surgeries and follow-up care for 200 underprivileged children.

“As we look forward to 2020, we will continue to execute on our proven growth strategy, which we expect will deliver double-digit top-line growth and adjusted EBITDA margin expansion. Given the strong fundamentals of our core business, combined with our acquisitions and the newly expanded MCT insurance coverage, we believe BioTelemetry is on track to have another record year.”




https://cdn.kscope.io/a3fa444fd1079dd7fdfa9b214e9d41b9-beatlogoa05.jpg

Fourth Quarter Financial Results

Revenue for the fourth quarter 2019 was $112.0 million compared to $103.6 million for the fourth quarter 2018, an increase of $8.4 million, or 8.1%.

Gross profit for the fourth quarter 2019 was $69.9 million, or 62.4% of revenue, compared to $63.9 million, or 61.7% of revenue, for the fourth quarter 2018.

On a GAAP basis, net income attributable to BioTelemetry, Inc. for the fourth quarter 2019 was $1.6 million, or $0.04 per diluted share, compared to net income attributable to BioTelemetry, Inc. of $10.4 million, or $0.29 per diluted share, for the fourth quarter 2018. The decline in net income attributable to BioTelemetry, Inc. was primarily due to an increase in general and administrative and sales and marketing expenses resulting from ongoing investment in infrastructure. The decline was also attributable to increases in other charges resulting primarily from our information technology incident, the change in the fair value of acquisition-related contingent consideration, an impairment of our equity method investment and an unfavorable foreign exchange impact.

On an adjusted basis1, net income attributable to BioTelemetry, Inc. for the fourth quarter 2019 was $17.8 million, or $0.48 per diluted share. This compares to adjusted net income attributable to BioTelemetry, Inc. of $20.1 million, or $0.56 per diluted share, for the fourth quarter 2018. Revenue growth is being offset by the impact of the ongoing investments in our sales force and technology. The details regarding adjusted net income are included in the reconciliation tables included in this release.

1 The Company believes that providing non-GAAP financial measures offers a meaningful representation of our performance, as we exclude expenses that are not necessary to support our ongoing business. We also make adjustments to facilitate year over year comparisons. Please refer to our “Reconciliation of GAAP to Non-GAAP Financial Measures” in this release for additional information.

Conference Call

BioTelemetry, Inc. will host an earnings conference call on Wednesday, February 26, 2020, at 5:00 PM Eastern Time. The call will be webcast on the investor information page of our website, www.gobio.com/investors/events. The call will be archived on our website for two weeks.

About BioTelemetry

BioTelemetry, Inc. is the leading remote medical technology company focused on delivery of health information to improve quality of life and reduce cost of care. We provide remote cardiac monitoring, centralized core laboratory services for clinical trials, remote blood glucose monitoring and original equipment manufacturing that serves both healthcare and clinical research customers. More information can be found at www.gobio.com.

Cautionary Statement Regarding Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in our future. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning. Examples of forward-looking statements include statements we make regarding the successful execution of our operating plan, our ability to increase demand for our products and services, to grow our market share, to expand in the European market, our expectations regarding revenue trends in our segments, and our growth expectations for 2020. Such


https://cdn.kscope.io/a3fa444fd1079dd7fdfa9b214e9d41b9-beatlogoa05.jpg

forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things: our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business; our ability to educate physicians and continue to obtain prescriptions for our products and services; changes to insurance coverage and reimbursement levels by Medicare and commercial payors for our products and services; our ability to attract and retain talented executive management and sales personnel; the commercialization of new competitive products; impact of the October 2019 information technology incident; our ability to obtain and maintain required regulatory approvals for our products, services and manufacturing facilities; changes in governmental regulations and legislation; adverse regulatory actions; our ability to obtain and maintain adequate protection of our intellectual property; interruptions or delays in the telecommunications systems that we use; our ability to successfully resolve outstanding legal proceedings; and the other factors that are described in “Part I; Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019.

We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required by law.

Contact:     BioTelemetry, Inc.
Heather C. Getz
Investor Relations
800-908-7103
investorrelations@biotelinc.com



https://cdn.kscope.io/a3fa444fd1079dd7fdfa9b214e9d41b9-beatlogoa05.jpg

BioTelemetry, Inc.
Consolidated Statements of Operations
(unaudited)
 
Three Months Ended
 
Year Ended
 
December 31,
 
December 31,
(in thousands, except per share data)
2019
 
2018
 
2019
 
2018
Revenue
$
112,034

 
$
103,603

 
$
439,107

 
$
399,472

Cost of revenue
42,117

 
39,657

 
164,833

 
148,986

Gross profit
69,917

 
63,946

 
274,274

 
250,486

Gross profit %
62.4
%
 
61.7
%
 
62.5
%
 
62.7
%
 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
General and administrative
32,248

 
27,951

 
120,093

 
109,736

Sales and marketing
12,857

 
10,314

 
50,664

 
42,849

Bad debt expense
5,383

 
5,311

 
21,768

 
22,222

Research and development
3,468

 
2,755

 
13,994

 
11,206

Other charges
7,102

 
3,036

 
15,004

 
14,659

Total operating expenses
61,058

 
49,367

 
221,523

 
200,672

 
 
 
 
 
 
 
 
Income from operations
8,859

 
14,579

 
52,751

 
49,814

 
 
 
 
 
 
 
 
Other expense:
 
 
 
 
 
 
 
Interest expense
(2,124
)
 
(2,447
)
 
(9,482
)
 
(9,429
)
Loss on equity method investments
(1,047
)
 
(8
)
 
(1,298
)
 
(246
)
Other non-operating (expense)/income, net
(430
)
 
822

 
(2,243
)
 
1,365

Total other expense, net:
(3,601
)
 
(1,633
)
 
(13,023
)
 
(8,310
)
 
 
 
 
 
 
 
 
Income before income taxes
5,258

 
12,946

 
39,728

 
41,504

(Provision for)/benefit from income taxes
(3,682
)
 
(2,553
)
 
(9,884
)
 
370

Net income
1,576

 
10,393

 
29,844

 
41,874

 
 
 
 
 
 
 
 
Net loss attributable to noncontrolling interests

 

 

 
(946
)
 
 
 
 
 
 
 
 
Net income attributable to BioTelemetry, Inc.
$
1,576

 
$
10,393

 
$
29,844

 
$
42,820

 
 
 
 
 
 
 
 
Net income per common share attributable to BioTelemetry, Inc.:
 
 
 
 
 
 
 
Basic
$
0.05

 
$
0.31

 
$
0.88

 
$
1.31

Diluted
$
0.04

 
$
0.29

 
$
0.82

 
$
1.20

 
 
 
 
 
 
 
 
Weighted average number of common shares outstanding:
 
 
 
 
 
 
 
Basic
34,002

 
33,363

 
33,948

 
32,709

Diluted
36,874

 
36,197

 
36,440

 
35,783




https://cdn.kscope.io/a3fa444fd1079dd7fdfa9b214e9d41b9-beatlogoa05.jpg

BioTelemetry, Inc.
Condensed Consolidated Balance Sheets
 
December 31,
(in thousands)
2019
 
2018
ASSETS
(unaudited)
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
68,614

 
$
80,889

Healthcare accounts receivable, net
71,851

 
37,754

Other accounts receivable, net
15,625

 
14,874

Inventory
5,738

 
7,323

Prepaid expenses and other current assets
6,505

 
5,820

Total current assets
168,333

 
146,660

 
 
 
 
Property and equipment, net
56,380

 
48,377

Intangible assets, net
129,596

 
129,653

Goodwill
301,321

 
238,814

Deferred tax assets
12,626

 
19,975

Other assets
17,464

 
3,322

Total assets
$
685,720

 
$
586,801

 
 
 
 
LIABILITIES AND EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
24,198

 
18,157

Accrued liabilities
27,318

 
24,689

Current portion of finance lease obligations
394

 
1,652

Current portion of long-term debt
3,844

 
5,125

Total current liabilities
55,754

 
49,623

 
 
 
 
Long-term portion of finance lease obligations
289

 
117

Long-term debt
190,823

 
193,424

Other long-term liabilities
71,937

 
33,152

Total liabilities
318,803

 
276,316

 
 
 
 
Total equity
366,917

 
310,485

 
 
 
 
Total liabilities and equity
$
685,720

 
$
586,801




https://cdn.kscope.io/a3fa444fd1079dd7fdfa9b214e9d41b9-beatlogoa05.jpg

BioTelemetry, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
Quarterly Non-GAAP Adjusted Net Income and Non-GAAP Adjusted Net Income Per Share
 
 
Three Months Ended
(Unaudited)
 
December 31, 2019
(in thousands, except per share data)
 
Income from operations
 
Income before income taxes
 
Net income attributable to BioTelemetry, Inc.
 
Net income per diluted share attributable to BioTelemetry, Inc.
GAAP
 
$
8,859

 
$
5,258

 
$
1,576

 
$
0.04

Non-GAAP adjustments:
 
 
 
 
 
 
 
 
Other charges (a)
 
7,102

 
7,102

 
7,102

 
0.19

Acquisition amortization (b)
 
3,727

 
3,727

 
3,727

 
0.10

Other expense adjustments (c)
 

 
1,382

 
1,382

 
0.04

Interest expense on deferred purchase consideration (d)
 

 
100

 
100

 

Income tax effect of adjustments (e)
 

 

 
(3,063
)
 
(0.08
)
Impact of NOL utilization (f)
 

 

 
6,947

 
0.19

Non-GAAP Adjusted
 
$
19,688

 
$
17,569

 
$
17,771

 
$
0.48


 
 
Three Months Ended
(Unaudited)
 
December 31, 2018
(in thousands, except per share data)
 
Income from operations
 
Income before income taxes
 
Net income attributable to BioTelemetry, Inc.
 
Net income per diluted share attributable to BioTelemetry, Inc.
GAAP
 
$
14,579

 
$
12,946

 
$
10,393

 
$
0.29

Non-GAAP adjustments:
 
 
 
 
 
 
 
 
Other charges (a)
 
3,036

 
3,036

 
3,036

 
0.08

Acquisition amortization (b)
 
3,267

 
3,267

 
3,267

 
0.09

Income tax effect of adjustments (e)
 

 

 
(56
)
 

Impact of NOL utilization (f)
 

 

 
3,459

 
0.10

Non-GAAP Adjusted
 
$
20,882

 
$
19,249

 
$
20,099

 
$
0.56


a.
In the fourth quarter 2019, other charges of $7.1 million were primarily due to $3.0 million of charges related to our October 2019 information technology incident, a $1.5 million unfavorable change in the fair value of acquisition-related contingent consideration, $1.3 million of integration and other expenses related to our acquisitions and $1.2 million of patent litigation and other legal costs. In the fourth quarter 2018, other charges of $3.0 million were primarily due to $2.2 million for integration and restructuring activities related to our acquisitions and $0.8 million for patent and other litigation.

b.
In the fourth quarter 2019 and 2018, we recognized $3.7 million and $3.3 million of expense, respectively, related to the amortization of acquisition-related intangibles assets. We have excluded this amortization of acquisition-related intangible assets from non-GAAP adjusted net income due to the non-operational nature of the expense. This amortization was recorded as a component of general and administrative expense.

c.
In the fourth quarter 2019, we had a non-cash charges for an impairment of our equity method investment of $1.0 million, an unrealized foreign exchange loss of $0.2 million and an impairment of a loan receivable of $0.2 million.

d.
In the fourth quarter 2019, we incurred $0.1 million of interest expense related to a portion of the Geneva Healthcare deferred purchase consideration.

e.
Represents the tax effect of the non-GAAP adjustments at the Company’s annual effective tax rate.

f.
After giving effect to taxes at the estimated annual effective tax rate on the adjustments, the utilization of net operating loss carryforwards had a $6.9 million and a $3.5 million positive impact on the fourth quarter 2019 and 2018, respectively.



https://cdn.kscope.io/a3fa444fd1079dd7fdfa9b214e9d41b9-beatlogoa05.jpg

BioTelemetry, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
Annual Non-GAAP Adjusted Net Income and Non-GAAP Adjusted Net Income Per Share
 
 
Year Ended
(Unaudited)
 
December 31, 2019
(in thousands, except per share data)
 
Income from operations
 
Income before income taxes
 
Net income attributable to BioTelemetry, Inc.
 
Net income per diluted share attributable to BioTelemetry, Inc.*
GAAP
 
$
52,751

 
$
39,728

 
$
29,844

 
$
0.82

Non-GAAP adjustments:
 
 
 
 
 
 
 
 
Other charges (g)
 
15,004

 
15,004

 
15,004

 
0.41

Acquisition amortization (h)
 
14,469

 
14,469

 
14,469

 
0.40

Other expense adjustments (i)
 

 
2,861

 
2,861

 
0.08

Interest expense on deferred purchase consideration (j)
 

 
340

 
340

 
0.01

Income tax effect of adjustments (k)
 

 

 
(8,129
)
 
(0.22
)
Impact of NOL utilization (l)
 

 

 
16,809

 
0.46

Non-GAAP Adjusted
 
$
82,224

 
$
72,402

 
$
71,198

 
$
1.95

* Total does not add due to rounding
 
 
 
 
 
 
 
 

 
 
Year Ended
(Unaudited)
 
December 31, 2018
(in thousands, except per share data)
 
Income from operations
 
Income before income taxes
 
Net income attributable to BioTelemetry, Inc.
 
Net income per diluted share attributable to BioTelemetry, Inc.*
GAAP
 
$
49,814

 
$
41,504

 
$
42,820

 
$
1.20

Non-GAAP adjustments:
 
 
 
 
 
 
 
 
Other charges (g)
 
14,659

 
14,659

 
14,659

 
0.41

Acquisition amortization (h)
 
13,119

 
13,119

 
13,119

 
0.37

Other expense adjustments, net (i)
 

 
(748
)
 
(748
)
 
(0.02
)
Income tax effect of adjustments (k)
 

 

 
(241
)
 
(0.01
)
(Benefit) of discrete items / NOL utilization (l)
 

 

 
(161
)
 

Non-GAAP Adjusted
 
$
77,592

 
$
68,534

 
$
69,448

 
$
1.94

* Total does not add due to rounding
 
 
 
 
 
 
 
 

g.
For the year ended December 31, 2019, other charges of $15.0 million were due primarily to $7.0 million of patent litigation and other legal costs, $4.9 million of integration and other expenses related to our acquisitions, $3.0 million of charges related to our October 2019 information technology incident and $0.4 million for other non-recurring activities, partially offset by a $0.2 million favorable change in the fair value of acquisition-related contingent consideration. For the year ended December 31, 2018, other charges of $14.7 million consisted of $10.1 million for the integration and restructuring activities related to our acquisitions, $2.6 million for patent litigation and other legal costs, a $1.8 million reserve for a note receivable with a bankrupt customer and $1.2 million of other costs primarily related to previous acquisitions, partially offset by a $0.7 million reduction in contingent consideration related to a 2016 acquisition.

h.
For the years ended December 31, 2019 and 2018, we recognized $14.5 million and $13.1 million of expense, respectively, related to the amortization of acquisition-related intangibles assets. We have excluded this amortization of acquisition-related intangible assets from non-GAAP adjusted net income due to the non-operational nature of the expense. This amortization was recorded as a component of general and administrative expense.

i.
For the year ended December 31, 2019, we had a non-cash charges for an unrealized foreign exchange loss of $2.4 million, an impairment of our equity method investment of $1.0 million and an impairment of a loan receivable of $0.2 million, partially offset by a $0.7 million gain associated with the termination of a former LifeWatch foreign pension plan. For the year ended December 31, 2018, we incurred $0.3 million of interest related to a ruling on an arbitration demand filed against LifeWatch prior to the acquisition. This was offset by an unrealized foreign exchange gain of $1.0 million.

j.
For the year ended December 31, 2019, we incurred $0.3 million of interest expense related to a portion of the Geneva Healthcare deferred purchase consideration.

k.
Represents the tax effect of the non-GAAP adjustments at the Company’s annual effective tax rate.



https://cdn.kscope.io/a3fa444fd1079dd7fdfa9b214e9d41b9-beatlogoa05.jpg

l.
After giving effect to taxes at the estimated annual effective tax rate on the adjustments, the utilization of net operating loss carryforwards had a $16.8 million positive impact on the year ended December 31, 2019. For the year ended December 31, 2018, the Company is excluding a $0.2 million benefit from discrete items.

BioTelemetry, Inc.
Reconciliation of GAAP to Non-GAAP Financial Measures
Quarterly and Annual Non-GAAP Adjusted EBITDA and EBITDA Margin

(Unaudited)
 
Three Months Ended
 
Year Ended
 
 
December 31,
 
December 31,
(in thousands)
 
2019
 
2018
 
2019
 
2018
Net income attributable to BioTelemetry, Inc. - GAAP
 
$
1,576

 
$
10,393

 
$
29,844

 
$
42,820

Net loss attributable to noncontrolling interest
 

 

 

 
(946
)
Provision for/(benefit from) income taxes
 
3,682

 
2,553

 
9,884

 
(370
)
Total other expense, net
 
3,601

 
1,633

 
13,023

 
8,310

Other charges
 
7,102

 
3,036

 
15,004

 
14,659

Depreciation and amortization expense (m)
 
12,067

 
9,883

 
42,575

 
39,637

Stock compensation expense
 
3,714

 
2,983

 
13,376

 
9,261

Non-GAAP Adjusted EBITDA
 
$
31,742

 
$
30,481

 
$
123,706

 
$
113,371

GAAP Net income as a percent of revenue
 
1.4
%
 
10.0
%
 
6.8
%
 
10.7
%
Non-GAAP Adjusted EBITDA margin
 
28.3
%
 
29.4
%
 
28.2
%
 
28.4
%

m.
For the three months and year ended December 31, 2019, depreciation and amortization expense excludes $0.4 million of expense related to the write-off of assets as a result of the dissolution of entities acquired as part of the LifeWatch acquisition. Similarly, for the three months and year ended December 31, 2018, we excluded $0.1 million and $0.5 million, respectively. These expenses are included in Other charges.


Quarterly and Annual Non-GAAP Free Cash Flow

(Unaudited)
 
Three Months Ended
 
Year Ended
 
 
December 31,
 
December 31,
(in thousands)
 
2019
 
2018
 
2019
 
2018
Cash provided by operating activities
 
$
14,948

 
$
28,459

 
$
67,550

 
$
72,746

Capital expenditures
 
(7,021
)
 
(7,139
)
 
(30,707
)
 
(24,637
)
Non-GAAP Free Cash Flow
 
$
7,927

 
$
21,320

 
$
36,843

 
$
48,109



Use of Non-GAAP Financial Measures

In addition to the results prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), this press release also includes certain financial measures which have been adjusted and are not in accordance with generally accepted accounting principles (“Non-GAAP financial measures”). These Non-GAAP financial measures include adjusted income from operations, adjusted income before income taxes, adjusted net income attributable to BioTelemetry, Inc., adjusted net income per diluted share attributable to BioTelemetry, Inc., adjusted EBITDA and free cash flow. In accordance with Regulation G of the Securities and Exchange Commission, we have provided a reconciliation of these Non-GAAP financial measures with the most directly comparable financial measure calculated in accordance with GAAP.

These Non-GAAP financial measures are not intended to replace GAAP financial measures. They are presented as supplemental measures of our performance in an effort to provide our stakeholders better visibility into our ongoing operating results and to allow for comparability to prior periods as well as to other companies’ results. Management uses these Non-GAAP financial measures to assess the financial


https://cdn.kscope.io/a3fa444fd1079dd7fdfa9b214e9d41b9-beatlogoa05.jpg

health of our ongoing operating performance. Management encourages our stakeholders to consider all of our financial measures and to not rely on any single financial measure to evaluate our performance.

Adjusted net income attributable to BioTelemetry, Inc. for the fourth quarter 2019 excludes other charges of $7.1 million, $3.7 million of amortization expense related to our acquisition-related intangible assets, $1.4 million of unrealized foreign currency loss, loss on equity method investment and loan impairments, $0.1 million of interest expense related to a portion of the Geneva Healthcare contingent consideration, the tax effect of these adjustments, as well as the impact from the utilization of our net operating loss carryforwards. Adjusted net income attributable to BioTelemetry, Inc. for the fourth quarter 2018 excludes other charges of $3.0 million, $3.3 million of amortization expense related to LifeWatch intangibles, the tax effect of these adjustments, as well as the impact from the utilization of our net operating loss carryforwards. By excluding expenses that are considered unnecessary to support the ongoing business, are nonrecurring in nature or which limit year over year comparability, we believe these Non-GAAP financial measures offer a meaningful representation of our ongoing operating performance. Included in these excluded items are transaction related expenses, primarily legal and professional fees, integration related expenses, primarily severance, legal fees related to patent litigation, amortization of intangibles from the LifeWatch and Geneva Healthcare acquisitions, costs related to the October information technology incident, costs related to restructuring programs aimed at streamlining operations and reducing future expense, as well as other one-time items. These excluded charges are not part of the ongoing operations, and therefore, not reflective of our core operations. We view patent litigation as an extreme measure not typically required in our industry to protect a company’s intellectual property and which has not been common practice for us. We commenced patent litigation proceedings after we uncovered specific evidence of four distinct cases of misappropriation and infringement. We can choose to resolve the outstanding matters and terminate the expense at any time. We also included the income tax effect of these adjustments.

In addition to adjusted income from operations, adjusted income before income taxes, adjusted net income attributable to BioTelemetry, Inc., adjusted net income per diluted share attributable to BioTelemetry, Inc. and free cash flow, we also present adjusted EBITDA. This Non-GAAP financial measure excludes loss from noncontrolling interest, income taxes, total other expense, net, other charges, depreciation and amortization and stock compensation expense. EBITDA is a widely accepted financial measure which we believe our stakeholders use to compare our ongoing financial performance to that of other companies. Adjusting our EBITDA for other charges and other one-time items is a meaningful financial measure as we believe it is an indication of our ongoing operations. In addition, we also add back stock-based compensation expense because it is non-cash in nature. Other companies in our industry may calculate adjusted EBITDA in a different manner.